DTC Act of 2025
Sponsored By: Representative Taylor
Introduced
Summary
This bill would require _drug price transparency in direct-to-consumer ads_. It would force many prescription drug and biological product ads that reach consumers to show a clear price baseline and give regulators authority to set how that price appears and is kept current.
Show full summary
- Families and patients would see the drug’s wholesale acquisition cost for a 30-day supply or a typical course in ads, and ads may note that actual out-of-pocket costs vary by insurance. There is an exemption for products with a wholesale acquisition cost under $35.
- Drug manufacturers and their agents would have to include the price disclosure in covered ads and could face civil money penalties up to $100,000 per violation. The bill directs the Department of Health and Human Services to write rules on how price information appears in audio and visual media and how quickly ads must be updated.
- Medicare and Medicaid oversight would get a new data and enforcement tool. The bill frames price disclosure as a way to help consumers compare costs and to inform federal efforts to slow drug spending growth.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Drug ads would show list price
Drug makers would need to show the wholesale acquisition cost (WAC) in direct-to-consumer ads for drugs paid by Medicare or Medicaid. The ad must show the WAC for a 30-day supply or a typical course of treatment. Ads with a WAC under $35 would be exempt. It would apply to consumer drug ads that already include required risk and benefit information. HHS would set how the price must appear and how fast ads must be updated within 1 year, and the disclosure would be in place by July 1, 2026. Ads may also say your out-of-pocket cost could be different based on your insurance.
Fines and funding to enforce price ads
HHS could fine a drug maker or its agent up to $100,000 for each ad that breaks the disclosure rule. The federal civil money penalty process would apply. This enforcement power would start upon enactment. The bill would also allow Congress to fund HHS as needed to run and enforce the rule; no dollar amount is set.
Sponsors & CoSponsors
Sponsor
Taylor
OH • R
Cosponsors
Schakowsky
IL • D
Sponsored 6/5/2025
Begich
AK • R
Sponsored 7/2/2025
Quigley
IL • D
Sponsored 7/2/2025
Bresnahan
PA • R
Sponsored 9/30/2025
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 9/30/2025
Nunn (IA)
IA • R
Sponsored 10/3/2025
Vindman
VA • D
Sponsored 10/21/2025
Hinson
IA • R
Sponsored 1/13/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in